Literature DB >> 15583859

Degradation of proinsulin C-peptide in kidney and placenta extracts by a specific endoprotease activity.

E Melles1, H Jörnvall, S Tryggvason, K Gemzell Danielsson, K Ekberg, K Tryggvason, J Wahren, T Bergman.   

Abstract

Degradation of proinsulin C-peptide in mouse kidney and human placenta extracts was studied using reverse-phase high-performance liquid chromatography and nano-electrospray mass spectrometry. In total, 15 proteolytic cleavage sites were identified in human and mouse C-peptides. Early sites included the peptide bonds N-terminal of Val/Leu10, Leu12, Leu21, Leu24 and Leu26 in different combinations for the two tissues and two peptides. Notably, these cleavages were N-terminal of a hydrophobic residue, and all but one N-terminal of Leu. A late degradation product of the human peptide detected in the kidney extract was the C-terminal hexapeptide, containing just one residue more than the biologically active C-terminal pentapeptide of C-peptide. We conclude that the degradation of C-peptide in kidney and placenta follows similar patterns, dominated by endopeptidase cleavages N-terminal of Leu.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583859     DOI: 10.1007/s00018-004-4313-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  50 in total

1.  Is slow coronary flow associated with inflammation?

Authors:  Jian-Jun Li; Bo Xu; Zi-Cheng Li; Jie Qian; Bing-Qi Wei
Journal:  Med Hypotheses       Date:  2005-11-08       Impact factor: 1.538

2.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

3.  Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.

Authors:  Miao-Pei Chen; Fu-Mei Chung; Dao-Ming Chang; Jack C-R Tsai; Han-Fen Huang; Shyi-Jang Shin; Yau-Jiunn Lee
Journal:  J Clin Endocrinol Metab       Date:  2005-10-18       Impact factor: 5.958

4.  Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.

Authors:  Fabia Brentano; Olivier Schorr; Caroline Ospelt; Joanna Stanczyk; Renate E Gay; Steffen Gay; Diego Kyburz
Journal:  Arthritis Rheum       Date:  2007-09

5.  Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow.

Authors:  Hasan Pekdemir; Gurbuz Polat; V Gökhan Cin; Ahmet Camsari; Dilek Cicek; M Necdet Akkus; Oben Doven; M Tuna Katircibasi; Necati Muslu
Journal:  Int J Cardiol       Date:  2004-10       Impact factor: 4.164

6.  Comparison of exercise QRS amplitude changes in patients with slow coronary flow versus significant coronary stenosis.

Authors:  Muhsin Turkmen; Irfan Barutcu; Ali Metin Esen; Osman Karakaya; Ozlem Esen; Yelda Basaran
Journal:  Jpn Heart J       Date:  2004-05

7.  Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes.

Authors:  N P E Kadoglou; N Sailer; A Moumtzouoglou; A Kapelouzou; H Tsanikidis; I Vitta; C Karkos; P E Karayannacos; T Gerasimidis; C D Liapis
Journal:  Exp Clin Endocrinol Diabetes       Date:  2009-10-15       Impact factor: 2.949

Review 8.  Minireview: adiposity, inflammation, and atherogenesis.

Authors:  Christopher J Lyon; Ronald E Law; Willa A Hsueh
Journal:  Endocrinology       Date:  2003-06       Impact factor: 4.736

9.  Clinical manifestations of slow coronary flow from acute coronary syndrome to serious arrhythmias.

Authors:  Beata Wozakowska-Kapłon; Justyna Niedziela; Paweł Krzyzak; Sebastian Stec
Journal:  Cardiol J       Date:  2009       Impact factor: 2.737

10.  Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes.

Authors:  Nikolaos P E Kadoglou; Fotios Iliadis; Nikoleta Angelopoulou; Nikolaos Sailer; Grigorios Fotiadis; Kleon Voliotis; Ioulia Vitta; Christos D Liapis; Miltiadis Alevizos
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

View more
  3 in total

Review 1.  Physiological effects and therapeutic potential of proinsulin C-peptide.

Authors:  Gina L C Yosten; Christine Maric-Bilkan; Patrizia Luppi; John Wahren
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-09-23       Impact factor: 4.310

2.  Development and Validation of a Novel LC-MS/MS Assay for C-Peptide in Human Serum.

Authors:  Benjamin Y Owusu; Hannah Pflaum; Russell Garner; North Foulon; Thomas J Laha; Andrew N Hoofnagle
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2020-12-28

3.  Streptozotocin-Induced Diabetes in a Mouse Model (BALB/c) Is Not an Effective Model for Research on Transplantation Procedures in the Treatment of Type 1 Diabetes.

Authors:  Michal Wszola; Marta Klak; Anna Kosowska; Grzegorz Tymicki; Andrzej Berman; Anna Adamiok-Ostrowska; Joanna Olkowska-Truchanowicz; Izabela Uhrynowska-Tyszkiewicz; Artur Kaminski
Journal:  Biomedicines       Date:  2021-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.